Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Institute of Oncology Research

    - PMLiVE

    Major prostate cancer screening trial launched in UK

    The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men

    - PMLiVE

    Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

    Around 55,100 cases of prostate cancer are diagnosed in the UK every year

    - PMLiVE

    Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use

    The authorisation approximately triples the number of patients eligible to receive the therapy

    - PMLiVE

    ICR researchers uncover genes responsible for tumour progression in prostate cancer

    The findings could pave the way for new treatment approaches that improve patient outcomes

    - PMLiVE

    Prostate cancer blood test with ‘unprecedented accuracy’ cuts biopsies by 50%

    There is currently no national screening programme for prostate cancer in the UK

    - PMLiVE

    ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

    The research could pave the way for the development of new drugs that prevent drug resistance

    - PMLiVE

    AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

    More than 52,000 cases of prostate cancer are diagnosed in the UK every year

    - PMLiVE

    ICR researchers identify potential treatment approach for acute myeloid leukaemia

    More than 3,100 people are diagnosed with the aggressive blood cancer in the UK every year

    - PMLiVE

    Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer

    Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis

    - PMLiVE

    J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study

    Approximately 300,000 new cases of the disease are diagnosed in the US every year

    - PMLiVE

    ICR researchers reveal benefits of personalised radiotherapy for bladder cancer patients

    More than 130,000 patients are treated with radiotherapy on the NHS every year

    - PMLiVE

    ICR researchers identify new drug target for advanced prostate cancer patients

    The team estimates that around 10% of patients have high levels of the BCL2 protein

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links